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                              Summary
   Both pharmacology and pharmacy are the sciences for understanding of
the drug effects. On discussing the ethcacy and safety of drugs on the basis
of pharmacy, the most important matter is bioavailability. In other words,
pharmacy may consist of the research for understanding of bioavailability and
the technology for controlling of bioavailability. Sometimes the bioavailability
of a drug varies hundred or thousand times with dosage form and resultantly
it affects the eMcacy and safety of a drug. Therefore, so many projects of
research and development of new drugs have been directed how to design the
dosage form and how to finish the dosage form as the pharmaceutical product.
    Here, the following five topics will be mentioned briefly: (1) cyclodextrin
inclusion compound which is concerned with an enhancement of bioavailability
of drug; (2) effervescent enteric coated tablet of levodopa which was developed
by Sankyo Company and registered recently; (3) topical dosage form for
carcinoma colli which is now under clinical investigation in cooperation with
the gynecologists; (4) oral mucosal dosage form which was tried for the ab-
sorption of insulin;(5) adhesive tablet for aphtha which is expected to be
registered in near future.
              Introduction
  Both pharmacology and pharmacy are the
sciences for understanding of drug effects.
The drug effect E is determined as a func-
tion of the three main factors A, B and C in
the following equation:
             E= f(A, B, C) ,
where A is the intrinsic activity, B the sen-
sitivity of body, and C the concentration of a
drug at the active site.
  Figure 1 shows how a drug effect is set on
* Guest lecture for Czechoslovak Society of Pharmacology,
and how pharmacology and pharmacy take
part in the research. A is related to the bio-
logical response determined by pharmacody-
namic process, as it is concerned with phar-
macology. C is related to the bioavailability
determined by pharmacokinetic process, as it
is concerned with pharmacy. B is the body
factor modifying both pharmacodynamic and
pharmacokinetic processes, as it is concerned
with both pharmacology and pharmacy.
  Therefore, pharmacology and pharmacy ap-
proach to the same target from the different
    Prague, September 14, 1981.
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Fig. 1. Fields Concerned with Pharmacology
      and Pharmacy
directions. The research of dosage forms as
in my talking today may be included in an
approach to the onset of drug effects from
pharmacy side.
  When we discuss the eMcacy and safety of
drugs on the basis of pharmacy, the most
important matter is bioavailability. In other
words, pharmacy may consist of the research
for understanding of bioavailability and the
technology for controlling of bioavailability.
  The definition of bioavailability at the pres-
ent is given as the amount of drug absorbed
and the rate of absorption with regard to the
drug concentration in systemic circulation.
But, strictly speaking, the topical concentra-
tion of drug should be considered in dermal
or topical dosage forms. Therefore, the def-
inition of bioavailability in a true sense should
include both the systemic bioavailability and
the topical bioavailability.
  Anyway, such bioavailability is controlled
by the dosage form of a drug. Sometimes
it varies hundred or thousand times with
dosage form, and resultantly it affects the
eMcacy and safety of drug.
  Therefore, so many projects of research and
development of new drugs have been directed
how to design the dosage form and how to
finish the dosage form as the product.
  Today I like to talk about the five topics brief-
ly: (1) Cyclodextrin inclusion compoundsi-3);
(2) Effervescent enteric coated tablet, which
was developed by Sankyo Company'i5) and
registered recently; (3) Topical dosage form
for carcinoma colli7•8) ; (4) Oral mucosal dosage
form, which was tried for the absorption of
insulin9'; (5) Adhesive tablet for aphtha.iO'
1• Cyclodextrin Inclusion Compounds'ny3)
  As a series of our works on cyclodextrins,
we have reported some findings in relation to
bioavailability of inclusion compounds of drugs
with cyclodextrins.
  Bioavailability of drug usually depends on
the dissolution rate of drug. As is well known,
the total area of the interface of gastro-in-
testinal tract, where the drug permeates, is
very huge. Someone says it is nearly equal
to that of a tennis court, in man. Therefore,
the drug in solution in the gastro-intestinal
tract is absorbed very easily. In other words,
the total absorption rate is controlled by the
dissolution rate of drug. So, the bioavailability
can be enhanced by an enhancement of the
dissolution rate of a drug. Many studies have
been done to make an improvement of dis-
solution rate of drugs for this purpose.
Cyclodextrin inclusion compounds afford a
promising means in this concepts. By the
way, the international symposium of cyclo-
dextrin will be held in Budapest, Hungary in
the end of September, 1981.
  As is known, cyclodextrin or another name
Schardinger dextrin consists of several residues
of D-glucose attached by cr-1-4 linkage to form
a cyclic molecule. There are three kinds of
cyclodextrins according to the size of molecule•
They are cr,P and r. Among them, we can
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get a and P commercially. P is the most
widely available.
  The past structural studies have indicated
that the diameter of opening of cylinder of
the one side is a little bit larger than the
other side. Figure 2 shows P-cyclodextrin,
for example.
  Cyclodextrin includes various kinds of mole-
cules in the cavity. It includes sometimes the
whole molecule and sometimes a part of the
molecule. This kind of inclusion compound
generally gives a good solubility.
2o
t,{i
   T
Fig. 2. P-Cyclodextrin
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  From a pharmaceutical peint of view, cyclo-
dextrin may be applicable to the formulation
and stabilization of various drugs. Especially,
if we can provide an inclusion compound of
a certain drug with cyclodextrin in a solid
powdered state, it may afford a preparation
for oral use, which is well soluble in the
gastro-intestinal fluid to enhance the bioavail-
ability and also may suppress such an adverse
reaction as the irritation to stomach.
  We attempted some studies to obtain the
inclusion compounds of non-steroidal anti-
inflammatory drugs and additionally other
slightly water soluble drugs with cr- and P-
cyclodextrin in the solid pewdered form. As
is well known, non-steroidal antiinflammatory
drugs are generally very slightly soluble in
water and also sometimes cause an adverse
reaction due to a stimulant property to stomach
upon oral administration.
  We tried to prepare inclusion compounds by
a freeze-drying method, and also we tried a
coprecipitation method
3 Å~ 10-3M drug in
20 ml of ethyl ether
(1) add 1 Å~ 10-3M cyclodextrin
  100 ml of water
(2) agitat'e well for 24 hr at
  room.temperature
(3) coo1 to pa
(4) wash with
  ethyl ether
(5) dry at 500
LEei2el
    Fig. 3 Methods for
  freeze-drying method
    5Å~ 10-`M drug
          (1) add 5Å~ 10-`M cyclodextrin
  in (2) dissolve in 35ml of water and7drops of
             28% aqueous ammonium solution
          (3) freeze-dry
          (4) dry at 500
          (5) wash with eth}"1 ether
     rl
  solution residue
               (6) dry in vacuo
                  at room
                  ternperature
          LEe!!el
Preparation of Inclusion Cotnpounds
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coprecipitation method in comparison with the
freeze-drying method, as shown in Fig. 3.i)
  According to the coprecipitation method, a
drug in ether and cyclodextrin in water were
mixed together with the molar ratio 1:1.
This procedure followed the most general
coprecipitation method to prepare inclusion
compounds. According to the freeze-drying
method, a drug and cyclodextrin with the
molar ratio 1 : 1 were dissolved in an aqueous
solution containing a small amount of ammonia
because the test drugs are slightly soluble
and acidic. Of course, ammonia was not de-
tecteq in the final product when checked using
Nessler'sreagent. Weascertainedalsobythin
layer chromatography that the drug was not
degradated during the procedure. The pro-
ducts by the both methods were washed with
ether. Therefore,ifthedrugwasnotincluded,
it was not detected in the aqueous solution
of' the final product.
  We found that the freeze-drying method
was successful in obtaining the inclusion com-
pounds. All of the thirteen antiinflammatory
drugs which we tested were included by this
method, while only four among the thirteen
were included by coprecipitation method,
  According to the powder X-ray diffractomet-
ry, the ptoduct was transformed to amorphous
one by freeze-drying, showing no crystalline
peak in the diffraction pattern. This wasthe
characteristic point of the freeze-dried inclu-
sion compounds of drugs. On the other hand,
by the coprecipitation method, the product
was obtained in a crystalline state. Of course
the X-ray diffraction pattern in this case was
different from that of the intact drug.
  We checked the dissolution rate of the prod-
ucts by a stationary disk method, and found
that cyclodextrin was remarkably effective in
increasing the dissolution rate of the drug
when freeze-dried. The product obtained by
the coprecipitation method dissolved faster
than the intact drug, but not so fast as the
freeze-dried one because the latter dissolved
incomparably faster than the former two, as
was considered due to the amorphous property
of the latter. Additionally, we checked that
the mixture, coprecipitates, and freeze-dried
samples of antiinflammatory drugs with poly-
ethylene glycol or polyvinylpyrrolidone all
dissolved well in aqueous media compared with
the freeze-dried cyclodextrin inclusion com-
pounds. However, cyclodextrin seemed pref-
erable to these kinds of water soluble synthet-
ic polymers because of the low hygroscopic
property and the high fluidity of the powdered
products. Moreover, cyclodextrin may have
an advantage over the others in the safety as
a drug additive. In this point of view also,
cyclodextrin seemed to afford a promising
means for pharmaceutical preparations.
  Actually, we had a chance to know that the
bioavailability of ibprofen, an antiinflammatory
drug, increased when administered orally to
rabbits in the form of powdered inclusion
compound with P-cyclodextrin, while such an
additive as dextrin had no effect. As is known,
a freeze-drying method is often applied to
obtain a well soluble powdered preparation.
Therefore, in order to exclude the effect of
freeze-drying, for each comparative experi-
ment, we used the drug which was freeze-
dried alone in the same way as in preparing
the inclusion compound.
  In order to confirm the result in the pre-
liminary experiment in rabbits as mentioned
above, we examined the bioavailability using
-- 32 --
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  Fig. 4. Blood Concentration Curves with
        Standard Error for Ketoprofen in
        Beagle Dogs after Oral Administration
        of 100 mg of Ketoprofen.
        e: ketoprofentP-cyclodextrin freeze-
           dried inclusion compound.
        o: freeze-dried ketoprofen.
beagle dogs.2)
  Figure 4 shows that the freeze-dried inclu-
sion compound with P-cyclodextrin was re-
markably effective in increasing the bioavail-
ability of ketoprofen. On measuring the area
under the curve up to 4 hours after adminis-
tration in beagle dogs, for example, it was 529o
larger for the inclusion compound of ketoprofen
than for the simply freeze-dried drug. This
result seems significant, and it indicates that
as a general property the freeze-dried inclusion
compound enhances the bioavailability of drug
though this may not always be true in practice.
We investigated the influence of inclusion
with P-cyclodextrin on the irritation to the
stomach of rats when administered orally.3)
The drugs used were indomethacin, flufenamic
acid and phenylbutazone. In the cases of in-
domethacin and flufenamic acid, there was no
significant difference in the bioavailability be-
tween the inclusion compound and the intact
drug. In the case of phenylbutazone, however,
the effect of the inclusion compound was
                  Proc. Hoshi Pharm. No. as. 1os1
statistically significant by t-test at 59e level.
Figure 5 shows the inside of the stomach of
Wister male rats incised along the greater
curvature 17 hours after oral administration.
The degree of injury was represented by the
point shown in the figure. We can find that
the injury was less in the rats which were
given the drug as the inclusion compound.
The reason is not clear why only the inclusion
compeund of phenylbutazone among the 'three
test drugs was effective in..reducing the injury
of stoMach by oral administration. Anyhow,
the result is very interesting and further in-
vestigation should be made to clear the reason.
One thing we can consider as the reason may
6e the combination of the inclusion and the
intrinsic property of the drug itself. As a
result, we may suggest that an inclusion com-
pound may be effective in reducing the stomach
irritation as its basic property, and some modi-
fication of the method of administration might
be useful to develop such the effectiveness of
inclusion compounds.
2. Efferyescent Enteric Coated Tablet of
  Levodopa4,s) •
  Figure 6 shows the pathway of levodopa
in the body and brain. Only the intact levo-
dopa can permeate through blood brain barrier.
Therefore, the blood concentration of levodopa
has relation to the drug effect. However, the
blood concentration is not always related with
the amount administered because of the deg-
radation to dopamine by decarboxylase. More-
over, if a high dose is administered, various
side effects appear, such as vomiting by the
stimulation to stomach. In order to enhance
the blood concentration of levodopa, there can
be the two ways considered. One is to enhance
--
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Fig. 6: Pathway of Levodopa in Body and Brain
the bioavailability of levodopa itself. The
other is to administer a combination with de-
carboxylase inhibitor. The present efferves-
cent enteric coated tablet i$ to enhance the
bioavailability of levodopa itself without using
the decarboxylase inhibitor.
  It is known that the dopamine decarboxylase
activity differs with the site in the intestinal
tract and that there is a site ,good for the
He
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  Fig. 7. Area under the Blood-concentration
        Curve (AUC) and Amount Remained
        in Intestinal Loop of Levodopa When
        Injected into Different Segments.
absorption of Ievodopa. Figure 7 shows the
difference in bioavailability of levodopa when
it is injected into different segments of the
intestinal 1oop of dogs. ' The results regarding
both the area under the curve and the amount
remained in the intestinal loop of levodopa
show that the main absorption site of levodopa
34
is the duodenum. Therefore, if it is possible
to bring the drug around the duodenum in
high concentration, we may get a high bio-
availability of levodopa.
  After wide basic investigations, the research
group of Sankyo Company established a for-
mula of an effervescent enteric coated tablet
of levodopa containing the materials as follows :
(1) sodium bicarbonate and tartaric acid for
effervescence; (2) magnesium alumino-meta-
silicate for tablet forming and acceleration of
the effervescence; (3) hydroxypropyl methyl
cellulose for subcoating; (4) hydroxypropyl
methyl cellulose phthalate-50 for enteric coat-
ing. Here, the use of magnesium alumino-
metasilicate is said to be the key point to
make a tablet formulation possible containing
a fairly large amount of levodopa and also to
accelerate the effervescence with sodium bi-
carbonate and tartaric acid. Among the de-
rivatives of hydroxypropyl methyl cellulose
phthalate, the number-50 used here was found
to be suitable to the dissolution of tablets in
the duodenum. The number-50 is informed
to be named because it dissolves around pH 5.0.
  As a preliminary experiment, a couple of
tablets containing a pigment in the same dos-
age form as designed for levodopa were ad-
ministered at the same time to dogs in com-
parison with the existing regular enteric
coated tablets prepared with cellulose acetate
phthalate. The couple of the new effervescent
enteric coated tablets dissolved around the
duodenum with a fairly accuracy, while those
of the existing one did not dissolve near the
same place. Moreover, it must be added that
two pieces of the new effervescent tablets
dissolved in a close place each other around
the duodenum while the existing regular en-
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teric coated ones did in a lower part of the
intestinal tract and also in separate places
each other.
  Figure 8 shows that the blood concentration
curves of levodopa and total dopamine in
comparison between the new effervescent en-
teric coated tablet and the existing stomach
soluble capsules of levodopa. Regarding the
rate of bioavailability of levodopa, the time
when the curve reached the maximum was
about one hour later for the tablet than for
the existing capsules. This is because the
new one is an enteric coated preparation.
However, regarding the extent of bioavaila-
bility of levodopa, the area under the curve
of the new tablet was more than two times,
though the amount administered of the new
one was 809o of the existing one. This result
demonstrated a success in enhancement of
bioavailability of levodopa. Additionally, the
new preparation was effective in lowering
such a side effect as vomiting because it did
not dissolve in the stomach.
  Then, they examined this new preparation
clinically. The same type of blood concentra-
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tion curve as in Fig. 8 was obtained in volun-
tary .patients; As a result of the clinical
evaluation, the usefulness of this new effer-
vescent enteric coated tablet was recognized
to overcome the existing capsules of levodopa
in some extent- Accordingly, the production
of this preparation was permitted by the
Japanese Government and registered already.
3. Topical Dosage for Carcinoma Colti7•8)
  We are now carrying out this investigation
in cooperation with the group of gynecologists
of Yokohama City University Hospital.
  Uterine cancers occupy about 259o of all
female cancers in Japan. Among them, carci-
noma colli occupies 909o. The carcinoma colli
is generally treated by a surgical operation,
that is, exterpation of the whole uterus, and
then the patient is taken care subsidiarily by
radiation therapy or a drug treatment. Such
surgical operation performs a cure with a high
accuracy, especially in early stage of carcinoma
colli. However, it often gives various bad
effects to the body, also it makes a serious
problem for young patients who want to be-
come pregnant. Therefore, if some dosage
form can be provided to make the drug reach
the cancer cells with a high selectivity, a drug
treatment for carcinoma colli may go beyond
the subsidiary therapy.
  On the early stage of carcinoma colli, cancer
cells stay around the epiderium. So, it seems
possible to bring about a cure by a topical
applieation of such an antitumor agent as
bleomycin which is known to be effective to
the epiderium cancer, There has been such
a repert that' a suppesitory containing bleo-
mycin was applied to the cervical canal, but
it seemed unsuccessful because the drug re-
36
lease was so rapid to cause an inflammation
of the healthy vaginal mucosa.
  Then, we tried to design a new topical
dosage form for carcinoma colli consisting of
hydroxypropyl cellulose. Thisideacamefrom
our previous works.6) We investigated pre-
viously the slow release property of a tablet
containing hydroxypropyl cellulose as a vehi-
cle, and also we investigated the adhesiveness
of a semisolid preparation containing hydroxy-
propyl cellulose. For the present study, we
combined hydroxypropyl cellulose and Carbopol
9sc. Carbopol 934 is carboxypolymethylene
produced by B. F. Goodrich Chemical Company.
We prepared the two types of dosage forms by
compression using special die and punches : (a)
disk preparations7) and (b) stick preparations.8)
We found that the preparations swelled well
without dispersing when they absorbed the
body fluid, sticking to the disease part with a
good adhesiveness.
  Carbopo1 934 has been used for cosmetics or
ointments, and its toxicity and topical effect
have been ireported to be negligible. We also
confirmed that the preparations without con-
taining the drug gave no injurious effect to
mucosa when we set them on Portio vagt'nalis
of voluntary patients for 24 hours.
  In order to design a suitable formula, we
investigated preliminarily the release rate of
pigment or the drug and the water absorption
of the preparations on the agar plate. We
considered the agar plate might'offer a simple
model of mucosa because it can keep an ade-
quate amount of water similar to the secreting
fluid which makes the preparations swell and
bring about a.release of drug. For the pre-
liminary experiment, such pigments as rosani-
line hydrochloride and briliant blue were
convenient to estimate or predict the release
of the drug from the disk both with the naked
eye and by a spectroscopy. Following a rough
estimation from the release rate of the pig-
ment, next the release of bleomycine was
measured by the determination of the amount
released on the agar plate to set up final
candidate formulas. As a result, the release
of drug on agar plate increased with an
increase in concentration of hydroxypropyl
cellulose, while the water absorption of the
preparation, which has relation to the adhesive-
ness to the disease part, increased with an
increase in concentration of Carbopo1 934.
  After the basic examinations, the prepara-
tions of bleomycin, carboquone and 5-fluoro-
uracil were employed for clinical examinations,
First, we administered one disk containing
30 mg of bleomycin once to voluntary patients
of carcinoma colli of early stage.') The disk
usally can be used by sticking to Portio vagz'-
nalis. Sometimes, however, it was inserted
partly into cervical canal, where the lesion
existed. When the disk was taken out of the
patient after 24 hours, it was enlarged by
swelling to about two times in diameter.
Many foams were observed in the swollen
gel-like part of the disk, and moreover an
opaque part was observed in the center of the
aggregate, where the secreting fluid did not
penetrate into. Therefore, a continuous re-
lease of drug might take place for longer than
24 hours. The sticks were inserted into cer-
vical canal of the patient who had cancerous
focus in the inner part of the canal.8) The
stick in swollen state can be taken out of the
patient. When the stick preparation of car-
boquone was taken out after 4 days, it was
kept fairly red. This means that the drug
37
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still remained in the preparation, as carbo-
quone is a red substance.
  When the Portio vagi'nalis with a part of
vagina, which was extirpated from the patient
after the present treatment using 150 mg bleo-
mycin in total, was subjected to coloscopic
observation, the cancerous lesion was changed
to a rough surface due to the necrosis caused
by the attack of bleomycin, but the normal
mucosa was not affected by bleomycin, as may
be a characteristic point of this dosage form.
  Figure 9 shows the schematic comparisons
in focus of cervix uteri before and after the
treatment by the present disk preparations.7)
The circle represents Portio vagi'nalis. The
external os of the uterus is inside of t-he circle.
The oblique lined part in the right circle in-
dicates the position and number of remnant
of cancerous focu3 observed in histological
section of the uterus which was removed after
the treatment by the present dosage form. In
the cases of 3 patients, any cancereus focus
was not found after the present local ,treat-
ment. In the other 6 patients of 9, the number
of focus decreased remarkably. Therefore,
we can say the local treatment using the pres-
ent dosage form containing bleomycin may
perform a considerable cure.
  Table I shows the result of the clinical ap-
plication of stick preparations.8) Bleomycin
and 5-fluorouracil gave a high percentage of
perfect disappearance of cancerous focus for
patients of stage zero. In the case of carbo-
quone, however, it gave higher percentage for
stage Ia than for stage zero, as was dithcult
to give an explanation for thereason. Perhaps
it seemed attributable to a difference in athnity
to tissue or a difference in mechanism of cell
killingactionamongthesedrugs. Forexample,
Proc. Hoshi Pharm. No. 23. 1ss1
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   Fig. 9. Schematic Comparison in Focus of Cervix Uteri before and after the Treatment
          by the Disk Preparation$.
Table I. Results of Clinical Application of the Stick Preparations of Bleomycin (BLM), Carboqone
       (CQ) and 5-Fluorouracil (5-FU) to Voluntary Patients with Carcinoma Cotli at Stages O and Ia
Stage
o
Ia
Drug
BLM
CQ
5-FU
BLM
CQ
5-FU
No. of patients
8
4
4
10
3
3
Dose in total
   (mg)
 25- 275
 18- 30
300-1350
 50- 325
 18- 42
1200-1500
Disappearancea)
   of focus
5
1
4
2
2
1
9o disap-
pearance
63
25
100
20
67
33
  a) Complete disappearance of the cancerous focus
     local therapy using a stick preparation.
bleomycin and 5-fluorouracil are soluble in
water, while carboquone is slightly soluble in
water. The application of 5-fluorouracil gave
a result Of 1oo9o disappearance of the focus
for the patients of stage zero,
  Anyhow, the present dosage form could re-
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in the cervix uteri extirpated from patients after
duce cancerous focus. Additionally, the medi-
cal doctors of our group told us that the
patients did not complain of pain during the
administration of carboquone in this dosage
form, as they had the different experience in
the case of suppository of the same drug. In
the cases of both disk and stick preparations
the duration of administration was for three
weeks at the longest. Therefore, a higher
percentage of cure might be expected if the
treatment could be continued for a longer
period.
  Recently, the technique and system of an
early detection of utrine cancer have been
developed, for example, by a mass screening,
Therefore, the treatment using the present
topical dosage form may afford a useful means
for the treatment of the patients in the early
stage of disease who dislike the surgical oper•
ation or for the patients to whom the opera•
tion and radiation therapy can not be effective,
Finally, it can be said that further investiga-
tions should be made to find more suitable
vehicles, active ingredients and shape of dos-
age form for an improvement of therapeutic
effect and safety.
4. 0ral Mucosa1 Dosage Form (Insulin)9'
  Our investigation of the previous dosage
form originally started to develop a usefulness
in a treatment for carcinoma colli. A new
dosage form usually can be applied to finish
                            a
                                x
                                 core. base
                   peripheral
                 (HPC:CP=1
                           x
Fig.
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a preparation of different drugs if it is suitable
from the therapeutic point of view. Then,
we are interested in applying the previous
dosage form to oral mucosal administration of
the drugs which can not be administered
orally. Insulin is the most typical one among
such drugs.
  We prepared a disk of combination of hy-
droxypropyl cellulose and Carbopo1 934 con-
taining insulin. It sticked on the oral mucosai
membrane with a good adhesiveness. How-
ever, first, any absorption of insulin did not
take place. Next, we prepared a new dosage
form, as shown in Fig. 10. This is formed
of double layers. The core part consists of
cacao butter base containing insulin. This
idea came from the existing report that insulin
is absorbed from lectal mucosal membrane
whenappliedincacaobuttersuppository. The
core part is covered with the base of the
combination of hydroxypropyl cellulose and
Carbopo1 934, compressed in a die with punches.
The surface of the one punch was semi-
spherical.
  When set on the oral mucosal membrane,
cacao butter in the core part melts, and the
           mucosal membrane
(cacao• butter)
               (a)
10. Schematic lllustration
   HPC : hydroxypropyl
                    gelation
            zzaElilil}im
                  (b)
 of the New Mucosal Dosage Form
cellulose. CP: Carbopo1 934.
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          Table II. Mucosal Dosage Forms of Insulin tested in the Present Experiment
Group
Aa)
B
C
Core-base
Cacao butter
   (mg)
50
40
35
Insulinb)
 (rng)
10
10
Na-glycocholate
    (rng)
5
Peripheral-basec)
   HPC: CP
   Åq1:2) (mg)
150
150
150
  a) Reference.
  b) 26.8I.U./mg, bovine crystalline insulin,
  c) HPC:hydroxypropyl cellulose; CP:
peripheral layer sticks on the membrane and
gets gel-like keeping the cacao butter inside.
Actually, the preparation sticked on the oral
mucosal membrane of a beagle dog with a
good adhesiveness when set on. The periph-
eral part of the preparation, which sticked
on the membrane, got gel-like, as was con-
firmed after one hour. This state was kept
for about 6 hours and then started to disappear.
  However, when the core part base consisted
of cacao butter alone, insulin was not absorbed.
Therefore, we investigated the effect of vari-
ous kinds of additives, for example, saponin,
polyethylene glycols and sodium glucocholate.
Finally, we found that sodium glucocholate
was effective. In Table II, the formula are
shown, that is; A contained no insulin, B
insulin in cacao butter alone and C insulin in
cacao butter with sodium glucocholate. The
mechanism of the increase with sodium gluco-
cholate should be investigated more in detail.
Figure 11 shows that blood sugar decreased
when C, the preparation in cacao butter with
sodium glucocholate, was admin,istered in bea-
gle dogs, showing about 409o decrease after
one hour. Measuring the plasma insulin by
the enzyme immunoassay, as shown in Fig.
12, we obtained the result similar to the de-
 Sigma Chem. Co.
Carbopo1 934.
      O123456
                  Time (hr)
     11. Change of Blood Sugar Levels after
         Mucosal Administration of the New
         Mucosal Dosage Form of Insulin in
         Beagle Dogs
         Each point represents the meanÅ}
         S.E. of 9 determination$.
         -A-: group A, ------: group B,
         -e-: group C.
crease of blood sugar in Fig. 11.
  Of course, there remained various problems
concerning this dosage form. The amount
absorbed was fairly low compared with the
amount absorbed, as the extent of bioavaila-
bility was about O.59o of that in intramuscular
administration. However, it was comparable
to the result in the existing report of the
lectal absorption from suppository. Carrying
out further investigations of the formula of
the preparation, we expect to enhance the
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  Fig. 12. Change of Plasma Insulin Levels
         after Mucosal Administration of the
         New Mucosal Dosage Forms of In-
         sulin in Beagle Dogs
         Each point represents the meanÅ}S.E.
         of 9 determinations.
         -A-: group A, -1-: group B,
         -e-: group C.
absorption some more in future. Anyhow we
like to say our trial may be the first case to
show the insulin is absorbed from the oral
mucosal membrane.
5• ' Adhesive Tablet for Aphtha'O)
  As an extension of the previous study, we
designed an adhesive tablet for aphtha. So
many people are suffered from aphtha in Japan.
Just recently, Teijin Ltd. has developed this
dosage form which we designed and has applied
to the government for the approval as anew
drug. We hope it will be registered in near
future.
  Figure 13 shows the dosage form, as is a
kind of double layers tablet. The adhesive
layer consists mainly of hydroxypropyl cellu-
lose and Carbopo1 934, containing triamcinolone
acetonide, antiinflammatory corticosteroid. The
supporting layer consists of lactose. It is
shown in Fig. 14 why the supporting layer is
neoessary. The tablet is applied to the disease
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     ADHEsivE LAyERA(ll/?ll'Z' '"x
                       SUPPORTING LAYER
    Chydroxypropyl K,, i /(LACTOSE)
    cellulose X ... 'x/!f)OITi
    + Carbopo1 934) "', ,)o.4-
                 ,--7q-
     Fig. I3. Adhesive Tal)Iet for Aphtha
        WET FINGER
           TTP
        --ti-mut.m.flFgE,gkV,gRAL
                  APHTHA
  Fig. 14. Application of the Adhesive Tablet
         to Aphtha
part of aphtha with a wet finger tip, as shown
in Fig. 14. If the tablet is made of only the
adhesive layer, it sticks first on the finger tip
adhesively and comes back with the tip when
applied. Therefore, the supporting layer,
which is formed of lactose and thus not so
sticky, is necessary and plays a good role for
the application.
  When the adhesive tablet is applied, it ab-
sorbs mucosal fluid and swells to form a gel-
like layer which covers the aphtha much
longer than the existing preparations such as
the ointment for aphtha. Lactose in the sup-
porting layer is taken away. The swollen
state was similar to the previous dosage form
which was tried in beagle dogs.
  The topical concentration of the drug was
determined using tritium-labeled triamcinolone
acetonide. When the same dose of the drug
was applied on the tongue of rats the drug
remained on the surface of tongue more and
longer in the case of the present dosage form
than in the case of the existing ointment, as
shown in Fig. 15. An explanation for this
result is given as that the adhesive tablet
forms the swollen gel-like aggregate which
Proc. Hoslii Pberm. No. es, 1981
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  Fig. 15. Amount of Tritium-labeled Triamci-
         nolone Acetonide (SH-TAA) Remained
         on the Surface of Tongue in Rats
         (meanÅ}s.e,, N=5)
stays adhesively on the surface of tongue for
a fairly long period while a fairly large amount
of the ointment is taken away by saliva.
  In the tongue tissue of rats, the drug from
the adhesive tablet was kept at a high level
for a long period, while a rapid decreasing
curve was obtained in the case of the existing
ointment and the level was one-fifth of the
tablet, as shown in Fig. 16. This is due to
the difference in the sustained release property
and the adhesiveness. The adhesive tablet
has a sustained release property and remains
adhesively on the surface of tongue.
  The microautoradiograms of the tongue tis-
sue were taken with the lapse of time after
the application of the adhesive tablet and the
existing ointment of tritium-labeled triamcino-
lone acetonide. In each photograph, the epi-
dermis, connective tissue and muscular layer
were recognized, and there were observed
the black silver particles which were exposed
to the tritium-labeled triamcinolone acetonide
molecules in the tongue tissue. Figure 17
shows the schematic summary of the micro-
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      16. AmountofTritium-labeledTriarnci-
         nolone Acetonide (SH-TAA) in the
         Tissue of Tongue in Rats (meanÅ}s.e.,
         N= 5)
autoradiograms. There is a difference in the
distribution of drug between the adhesive
tablet and the existing ointment. In the ad-
hesive tablet, the drug stayed for 30 minutes
on the tongue surface, penetrated continuously
into the epidermis and resultantly was kept
at a certain level in the connective tissue and
the muscular layer for a long period. On the
other hand, in the existing ointment, the drug
is taken away easily from the tongue surface,
and resultantly a small amount of drug pene-
trated into the epidermis. Finally, the con-
centration of the drug is low in the connective
tissue and the muscular layer,
  As I mentioned already, the clinical trial
was finished. There was such an example
that the adhesive tablet was applied only to
the biggest one of the several aphthas of the
same patient, which was almost cured after
the treatment for two days while the other
small aphthas showed no change. After 7
days all the aphthas disappeared. As another
example, the tablet was applied to an aphtha
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Average amount
Side effect
Improvement
Usefulness
administered/day
Adhesive tablet
47.5 F,G
None
92.09o
92.09o
Ointment
495.0 ltG
none
67.49o
72.19e
T=3.98 (PÅqO.OOI)
T= 3.99 (PÅqO.OOI)
on the under lip, a kind of Bechet syndrome, was better in the tablet than in the ointment.
performing a cure after 5 days. Additionally,adouble blind clinical test was
  Summarizing the results of the comparative done in comparison with the placebo which
clinical teste in Table III, the average dose of did not contain triamcinolone acetonide. Re-
traiamcinolone acetonide per day in the ad- garding the improvement, the active was ef-
hesive tablet was about one-tenth of that in fective in 90.59o and the placebo 79.89e.
the existing ointment. Any side effect was The clinical usefulness by doctors' global
not found both in the adhesive tablet and in judgement was 77.99o for the active and 64.49o
theexistingointment. Regardingtheimprove- for the placebo. It is very interesting that
ment of aphtha, the adhesive tablet was the placebowasfairlyeffective. Thismaybe
more effective than the existing ointment at due to the dosage form which protect the
a statistically significant level. The clinical aphtha by the swollen gel-like layer while
usefulness by the doctors' global judgement applied.
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